Do analysts recommend DRIO or AIFF?

DarioHealth currently has a consensus target price of $10.00, suggesting a potential upside of 38.89%. Given DarioHealth's stronger consensus rating and higher possible upside, equities research analysts plainly believe DarioHealth is more favorable than Firefly Neuroscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DarioHealth 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Firefly Neuroscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer DRIO or AIFF?

In the previous week, Firefly Neuroscience had 3 more articles in the media than DarioHealth. MarketBeat recorded 4 mentions for Firefly Neuroscience and 1 mentions for DarioHealth. Firefly Neuroscience's average media sentiment score of 0.78 beat DarioHealth's score of 0.00 indicating that Firefly Neuroscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DarioHealth 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Firefly Neuroscience 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend AIFF or HIT?

Health In Tech has a consensus price target of $3.50, indicating a potential upside of 301.79%. Given Health In Tech's stronger consensus rating and higher probable upside, analysts plainly believe Health In Tech is more favorable than Firefly Neuroscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Firefly Neuroscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Health In Tech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Do analysts rate ONMD or AIFF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OneMedNet 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Firefly Neuroscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to ONMD or AIFF?

In the previous week, OneMedNet had 2 more articles in the media than Firefly Neuroscience. MarketBeat recorded 6 mentions for OneMedNet and 4 mentions for Firefly Neuroscience. OneMedNet's average media sentiment score of 0.93 beat Firefly Neuroscience's score of 0.78 indicating that OneMedNet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OneMedNet 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Firefly Neuroscience 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer HCTI or AIFF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Healthcare Triangle 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Firefly Neuroscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor HCTI or AIFF?

In the previous week, Firefly Neuroscience had 2 more articles in the media than Healthcare Triangle. MarketBeat recorded 4 mentions for Firefly Neuroscience and 2 mentions for Healthcare Triangle. Firefly Neuroscience's average media sentiment score of 0.78 beat Healthcare Triangle's score of 0.00 indicating that Firefly Neuroscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Healthcare Triangle 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Firefly Neuroscience 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate AIFF or ACON?

Aclarion has a consensus price target of $7.50, suggesting a potential upside of 197.62%. Given Aclarion's stronger consensus rating and higher probable upside, analysts plainly believe Aclarion is more favorable than Firefly Neuroscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Firefly Neuroscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor AIFF or ACON?

In the previous week, Firefly Neuroscience had 3 more articles in the media than Aclarion. MarketBeat recorded 4 mentions for Firefly Neuroscience and 1 mentions for Aclarion. Firefly Neuroscience's average media sentiment score of 0.78 beat Aclarion's score of 0.00 indicating that Firefly Neuroscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Firefly Neuroscience 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclarion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Firefly Neuroscience (AIFF) Competitors

$1.26 -0.02 (-1.56%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.23 -0.03 (-2.70%)

As of 09/18/2026 08:00 PM Eastern

Compare

AIFF vs. DRIO, HIT, ONMD, HCTI, and ACON

Should you buy Firefly Neuroscience stock or one of its competitors? Firefly Neuroscience's main competitors and comparable companies include DarioHealth (DRIO), Health In Tech (HIT), OneMedNet (ONMD), Healthcare Triangle (HCTI), and Aclarion (ACON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Firefly Neuroscience compare to DarioHealth?

DarioHealth (NASDAQ:DRIO) and Firefly Neuroscience (NASDAQ:AIFF) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

DarioHealth has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Firefly Neuroscience has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

33.4% of DarioHealth shares are owned by institutional investors. Comparatively, 5.0% of Firefly Neuroscience shares are owned by institutional investors. 3.5% of DarioHealth shares are owned by company insiders. Comparatively, 6.9% of Firefly Neuroscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

DarioHealth has a net margin of -169.87% compared to Firefly Neuroscience's net margin of -506.23%. DarioHealth's return on equity of -54.81% beat Firefly Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DarioHealth	-169.87%	-54.81%	-33.36%
Firefly Neuroscience	-506.23%	-90.17%	-72.05%

DarioHealth currently has a consensus target price of $10.00, suggesting a potential upside of 38.89%. Given DarioHealth's stronger consensus rating and higher possible upside, equities research analysts plainly believe DarioHealth is more favorable than Firefly Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Firefly Neuroscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Firefly Neuroscience has lower revenue, but higher earnings than DarioHealth. Firefly Neuroscience is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$22.36M	3.16	-$41.71M	-$6.13	N/A
Firefly Neuroscience	$1.14M	17.34	-$19.88M	-$0.59	N/A

In the previous week, Firefly Neuroscience had 3 more articles in the media than DarioHealth. MarketBeat recorded 4 mentions for Firefly Neuroscience and 1 mentions for DarioHealth. Firefly Neuroscience's average media sentiment score of 0.78 beat DarioHealth's score of 0.00 indicating that Firefly Neuroscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DarioHealth	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Firefly Neuroscience	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

DarioHealth beats Firefly Neuroscience on 10 of the 16 factors compared between the two stocks.

How does Firefly Neuroscience compare to Health In Tech?

Firefly Neuroscience (NASDAQ:AIFF) and Health In Tech (NASDAQ:HIT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Health In Tech has a consensus price target of $3.50, indicating a potential upside of 301.79%. Given Health In Tech's stronger consensus rating and higher probable upside, analysts plainly believe Health In Tech is more favorable than Firefly Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Firefly Neuroscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Health In Tech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Health In Tech has higher revenue and earnings than Firefly Neuroscience. Health In Tech is trading at a lower price-to-earnings ratio than Firefly Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Firefly Neuroscience	$1.14M	17.34	-$19.88M	-$0.59	N/A
Health In Tech	$32.83M	1.74	-$4.59M	-$0.07	N/A

Health In Tech has a net margin of 0.00% compared to Firefly Neuroscience's net margin of -506.23%. Health In Tech's return on equity of 0.00% beat Firefly Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Firefly Neuroscience	-506.23%	-90.17%	-72.05%
Health In Tech	N/A	N/A	N/A

Firefly Neuroscience has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market. Comparatively, Health In Tech has a beta of 2.72, meaning that its stock price is 172% more volatile than the broader market.

5.0% of Firefly Neuroscience shares are owned by institutional investors. 6.9% of Firefly Neuroscience shares are owned by insiders. Comparatively, 77.7% of Health In Tech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Firefly Neuroscience had 4 more articles in the media than Health In Tech. MarketBeat recorded 4 mentions for Firefly Neuroscience and 0 mentions for Health In Tech. Firefly Neuroscience's average media sentiment score of 0.78 beat Health In Tech's score of 0.00 indicating that Firefly Neuroscience is being referred to more favorably in the media.

Company	Overall Sentiment
Firefly Neuroscience	Positive
Health In Tech	Neutral

Summary

Health In Tech beats Firefly Neuroscience on 12 of the 17 factors compared between the two stocks.

How does Firefly Neuroscience compare to OneMedNet?

OneMedNet (NASDAQ:ONMD) and Firefly Neuroscience (NASDAQ:AIFF) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

OneMedNet has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Firefly Neuroscience has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OneMedNet	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Firefly Neuroscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Firefly Neuroscience has a net margin of -506.23% compared to OneMedNet's net margin of -584.20%. OneMedNet's return on equity of 0.00% beat Firefly Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OneMedNet	-584.20%	N/A	-521.20%
Firefly Neuroscience	-506.23%	-90.17%	-72.05%

OneMedNet has higher revenue and earnings than Firefly Neuroscience. OneMedNet is trading at a lower price-to-earnings ratio than Firefly Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OneMedNet	$1.36M	30.52	-$2.80M	-$0.16	N/A
Firefly Neuroscience	$1.14M	17.34	-$19.88M	-$0.59	N/A

1.0% of OneMedNet shares are owned by institutional investors. Comparatively, 5.0% of Firefly Neuroscience shares are owned by institutional investors. 50.2% of OneMedNet shares are owned by company insiders. Comparatively, 6.9% of Firefly Neuroscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, OneMedNet had 2 more articles in the media than Firefly Neuroscience. MarketBeat recorded 6 mentions for OneMedNet and 4 mentions for Firefly Neuroscience. OneMedNet's average media sentiment score of 0.93 beat Firefly Neuroscience's score of 0.78 indicating that OneMedNet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OneMedNet	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Firefly Neuroscience	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

OneMedNet beats Firefly Neuroscience on 9 of the 13 factors compared between the two stocks.

How does Firefly Neuroscience compare to Healthcare Triangle?

Healthcare Triangle (NASDAQ:HCTI) and Firefly Neuroscience (NASDAQ:AIFF) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Healthcare Triangle has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Firefly Neuroscience has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market.

In the previous week, Firefly Neuroscience had 2 more articles in the media than Healthcare Triangle. MarketBeat recorded 4 mentions for Firefly Neuroscience and 2 mentions for Healthcare Triangle. Firefly Neuroscience's average media sentiment score of 0.78 beat Healthcare Triangle's score of 0.00 indicating that Firefly Neuroscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Healthcare Triangle	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Firefly Neuroscience	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Healthcare Triangle	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Firefly Neuroscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Healthcare Triangle has higher revenue and earnings than Firefly Neuroscience. Firefly Neuroscience is trading at a lower price-to-earnings ratio than Healthcare Triangle, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Healthcare Triangle	$13.89M	0.84	-$9.48M	-$33.52	N/A
Firefly Neuroscience	$1.14M	17.34	-$19.88M	-$0.59	N/A

0.3% of Healthcare Triangle shares are owned by institutional investors. Comparatively, 5.0% of Firefly Neuroscience shares are owned by institutional investors. 0.1% of Healthcare Triangle shares are owned by insiders. Comparatively, 6.9% of Firefly Neuroscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Healthcare Triangle has a net margin of -66.85% compared to Firefly Neuroscience's net margin of -506.23%. Firefly Neuroscience's return on equity of -90.17% beat Healthcare Triangle's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Healthcare Triangle	-66.85%	-125.45%	-36.06%
Firefly Neuroscience	-506.23%	-90.17%	-72.05%

Summary

Firefly Neuroscience beats Healthcare Triangle on 7 of the 13 factors compared between the two stocks.

How does Firefly Neuroscience compare to Aclarion?

Firefly Neuroscience (NASDAQ:AIFF) and Aclarion (NASDAQ:ACON) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

5.0% of Firefly Neuroscience shares are held by institutional investors. Comparatively, 7.5% of Aclarion shares are held by institutional investors. 6.9% of Firefly Neuroscience shares are held by insiders. Comparatively, 0.0% of Aclarion shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Aclarion has lower revenue, but higher earnings than Firefly Neuroscience. Firefly Neuroscience is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Firefly Neuroscience	$1.14M	17.34	-$19.88M	-$0.59	N/A
Aclarion	$80K	90.72	-$7.23M	-$7.40	N/A

Firefly Neuroscience has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Aclarion has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market.

Firefly Neuroscience has a net margin of -506.23% compared to Aclarion's net margin of -10,948.81%. Aclarion's return on equity of -59.34% beat Firefly Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Firefly Neuroscience	-506.23%	-90.17%	-72.05%
Aclarion	-10,948.81%	-59.34%	-56.12%

Aclarion has a consensus price target of $7.50, suggesting a potential upside of 197.62%. Given Aclarion's stronger consensus rating and higher probable upside, analysts plainly believe Aclarion is more favorable than Firefly Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Firefly Neuroscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Firefly Neuroscience had 3 more articles in the media than Aclarion. MarketBeat recorded 4 mentions for Firefly Neuroscience and 1 mentions for Aclarion. Firefly Neuroscience's average media sentiment score of 0.78 beat Aclarion's score of 0.00 indicating that Firefly Neuroscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Firefly Neuroscience	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclarion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aclarion beats Firefly Neuroscience on 10 of the 16 factors compared between the two stocks.

Get Firefly Neuroscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIFF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIFF vs. The Competition

Export

Metric	Firefly Neuroscience	Healthcare Technology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$19.77M	$1.72B	$7.24B	$13.19B
Dividend Yield	N/A	4.71%	2.57%	12.81%
P/E Ratio	-2.14	20.07	275.49	25.40
Price / Sales	17.34	89.94	646.01	89.45
Price / Cash	N/A	31.60	76.25	51.42
Price / Book	2.21	6.14	10.46	6.33
Net Income	-$19.88M	-$18.66M	$3.49B	$358.33M
7 Day Performance	17.76%	1.79%	0.59%	1.12%
1 Month Performance	16.67%	1.77%	-1.74%	-2.39%
1 Year Performance	-56.40%	-14.53%	18.13%	5.35%

Firefly Neuroscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIFF Firefly Neuroscience	0.8013 of 5 stars	$1.26 -1.6%	N/A	-56.4%	$19.77M	$1.14M	N/A	17	News Coverage High Trading Volume
DRIO DarioHealth	3.7462 of 5 stars	$6.82 -3.0%	$10.00 +46.6%	+9.1%	$68.89M	$21.00M	N/A	200
HIT Health In Tech	2.1915 of 5 stars	$0.94 +0.6%	$3.50 +273.7%	-75.7%	$61.37M	$32.83M	N/A	79	Gap Up
ONMD OneMedNet	1.3414 of 5 stars	$0.68 -1.0%	N/A	-25.8%	$40.65M	$1.36M	N/A	2	News Coverage Gap Up
HCTI Healthcare Triangle	0.8498 of 5 stars	$0.75 -4.8%	N/A	-99.5%	$11.80M	$13.89M	N/A	80	News Coverage Short Interest Decrease Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIFF) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Firefly Neuroscience (AIFF) Competitors

AIFF vs. DRIO, HIT, ONMD, HCTI, and ACON

How does Firefly Neuroscience compare to DarioHealth?

Summary

How does Firefly Neuroscience compare to Health In Tech?

Summary

How does Firefly Neuroscience compare to OneMedNet?

Summary

How does Firefly Neuroscience compare to Healthcare Triangle?

Summary

How does Firefly Neuroscience compare to Aclarion?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIFF vs. The Competition

Firefly Neuroscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Firefly Neuroscience (AIFF) Competitors

AIFF vs. DRIO, HIT, ONMD, HCTI, and ACON

How does Firefly Neuroscience compare to DarioHealth?

Which has more risk & volatility, DRIO or AIFF?

Do insiders & institutionals hold more shares of DRIO or AIFF?

Is DRIO or AIFF more profitable?

Do analysts recommend DRIO or AIFF?

Which has stronger earnings & valuation, DRIO or AIFF?

Does the media prefer DRIO or AIFF?

Summary

How does Firefly Neuroscience compare to Health In Tech?

Do analysts recommend AIFF or HIT?

Which has preferable earnings & valuation, AIFF or HIT?

Is AIFF or HIT more profitable?

Which has more volatility and risk, AIFF or HIT?

Do insiders and institutionals believe in AIFF or HIT?

Does the media favor AIFF or HIT?

Summary

How does Firefly Neuroscience compare to OneMedNet?

Which has more risk and volatility, ONMD or AIFF?

Do analysts rate ONMD or AIFF?

Is ONMD or AIFF more profitable?

Which has higher earnings & valuation, ONMD or AIFF?

Do institutionals & insiders believe in ONMD or AIFF?

Does the media refer more to ONMD or AIFF?

Summary

How does Firefly Neuroscience compare to Healthcare Triangle?

Which has more volatility and risk, HCTI or AIFF?

Does the media favor HCTI or AIFF?

Do analysts prefer HCTI or AIFF?

Which has better valuation and earnings, HCTI or AIFF?

Do insiders & institutionals hold more shares of HCTI or AIFF?

Is HCTI or AIFF more profitable?

Summary

How does Firefly Neuroscience compare to Aclarion?

Do insiders and institutionals hold more shares of AIFF or ACON?

Which has preferable valuation and earnings, AIFF or ACON?

Which has more volatility & risk, AIFF or ACON?

Is AIFF or ACON more profitable?

Do analysts rate AIFF or ACON?

Does the media favor AIFF or ACON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIFF vs. The Competition

Firefly Neuroscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools